| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2024―Apr―23 |
Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines |
Congrui Zhu, Shengmei Pang, Jiaqi Liu, Qiangde Duan |
| 2 |
[GO] |
2023―Dec―18 |
Comment on “Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study” |
Wen-Bin Yeh, Wei-Kai Lee, Hui-Yuan Chen, Su-Boon Yong, Cheuk-Kwan Sun |
| 3 |
[GO] |
2023―Dec―18 |
Comment on: “Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study” |
Tsung-Wei Chang, Cheng-Hsien Hung |
| 4 |
[GO] |
2023―Dec―18 |
Reply to the Comments on “Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study” |
Thomas Yen-Ting Chen, Qianru Zhang, Yao-Min Hung, Renin Chang, Shiow-Ing Wang, James Cheng-Chung Wei |
| 5 |
[GO] |
2023―Sep―04 |
Correction to: Remdesivir: A Review in COVID-19 |
Hannah A. Blair |
| 6 |
[GO] |
2023―Aug―17 |
Remdesivir: A Review in COVID-19 |
Hannah A. Blair |
| 7 |
[GO] |
2023―May―19 |
Correction to: Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study |
Thomas Yen-Ting Chen, Shiow-Ing Wang, Yao-Min Hung, Joshua J. Hartman, Renin Chang, James Cheng-Chung Wei |
| 8 |
[GO] |
2023―May―11 |
Correction to: Comment on: ‘Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know?’ |
Chia Siang Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan |
| 9 |
[GO] |
2023―May―11 |
Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study |
Thomas Yen-Ting Chen, Shiow-Ing Wang, Yao-Min Hung, Joshua J. Hartman, Renin Chang, James Cheng-Chung Wei |
| 10 |
[GO] |
2023―May―04 |
Authors’ Reply to Chia Siang Kow et al.: Comment on: ‘Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know So Far?’ |
Alexia Plocque, Francois Philippart |
| 11 |
[GO] |
2023―May―04 |
Interleukin-6 Receptor Inhibitors and long COVID |
Chia Siang Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan |
| 12 |
[GO] |
2023―Jan―24 |
Risk of COVID-19 Diagnosis and Hospitalisation in Patients with Osteoarthritis or Back Pain Treated with Ibuprofen Compared to Other NSAIDs or Paracetamol: A Network Cohort Study |
Junqing Xie, James T. Brash, Cigdem Turkmen, Stefan Driessen, Giustino Varrassi, George Argyriou, Sarah Seager, Christian Reich, Daniel Prieto-Alhambra |
| 13 |
[GO] |
2022―Dec―12 |
Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know So Far? |
Alexia Plocque, Christie Mitri, Charlène Lefèvre, Olivier Tabary, Lhousseine Touqui, Francois Philippart |
| 14 |
[GO] |
2022―Dec―07 |
The Struggle to End a Millennia-Long Pandemic: Novel Candidate and Repurposed Drugs for the Treatment of Tuberculosis |
Brett D. Edwards, Stephen K. Field |
| 15 |
[GO] |
2022―Feb―12 |
Comment on: “Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence” |
Mario Gennaro Mazza, Benedetta Vai, Livia De Picker, Francesco Benedetti, Raffaella Zanardi |
| 16 |
[GO] |
2022―Feb―12 |
Authors’ Reply to Mazza et al.: “Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence” |
Eric J. Lenze, Angela M. Reiersen, Shelley N. Facente |
| 17 |
[GO] |
2021―Dec―16 |
Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Use Associated with Reduced Mortality and Other Disease Outcomes in US Veterans with COVID-19 |
John G. Rizk, Cachet Wenziger, Diana Tran, Leila Hashemi, Hamid Moradi, Elani Streja, Amrita Ahluwalia |
| 18 |
[GO] |
2021―Dec―01 |
Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence |
Shelley N. Facente, Angela M. Reiersen, Eric J. Lenze, David R. Boulware, Jeffrey D. Klausner |
| 19 |
[GO] |
2021―Aug―28 |
Reply to Zhang and Zhu “MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19” |
Nadine Ahmed, John Paul Pezacki |
| 20 |
[GO] |
2021―Aug―28 |
Comment on: “MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19” |
Song Zhang, Feng Zhu |
| 21 |
[GO] |
2021―May―28 |
Comment on: “Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry” |
Alpo Vuorio, Petri T. Kovanen |
| 22 |
[GO] |
2021―Mar―29 |
Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry |
José David Torres-Peña, Luis M. Pérez-Belmonte, Francisco Fuentes-Jiménez, Mª Dolores López Carmona, Pablo Pérez-Martinez, José López-Miranda, Francisco Javier Carrasco Sánchez, Juan Antonio Vargas Núñez, Esther del Corral Beamonte, Jeffrey Oskar Magallanes Gamboa, Andrés González García, Julio González Moraleja, Andrés Cortés Troncoso, María Luisa Taboada Martínez, María del Pilar del Fidalgo Montero, José Miguel Seguí Ripol, Ricardo Gil Sánchez, Diana Alegre González, Ramon Boixeda, Begoña Cortés Rodríguez, Javier Ena, Gema María García García, Ana Ventura Esteve, José Manuel Ramos Rincón, Ricardo Gómez-Huelgas |
| 23 |
[GO] |
2021―Mar―08 |
BNT162b2 mRNA COVID-19 Vaccine: First Approval |
Yvette N. Lamb |
| 24 |
[GO] |
2021―Feb―27 |
MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19 |
Christine Hum, Julia Loiselle, Nadine Ahmed, Tyler A. Shaw, Caroline Toudic, John Paul Pezacki |
| 25 |
[GO] |
2020―Nov―05 |
Pharmacotherapy for Hospitalized Patients with COVID-19: Treatment Patterns by Disease Severity |
Kueiyu Joshua Lin, Sebastian Schneeweiss, Helen Tesfaye, Elvira D’Andrea, Jun Liu, Joyce Lii, Shawn N. Murphy, Joshua J. Gagne |
| 26 |
[GO] |
2020―Oct―17 |
Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review |
Fabrizio Cantini, Delia Goletti, Linda Petrone, Saied Najafi Fard, Laura Niccoli, Rosario Foti |
| 27 |
[GO] |
2020―Sep―03 |
Comment on: “Pharmaco-Immunomodulatory Therapy in COVID-19” |
Dimitrios A. Vrachatis, Sotiria G. Giotaki, George Giannopoulos, Spyridon Deftereos, Bernhard Reimers |
| 28 |
[GO] |
2020―Sep―03 |
Authors’ Reply to Vrachatis et al. “Pharmaco-Immunomodulatory Therapy in COVID-19” |
John G. Rizk, Kamyar Kalantar-Zadeh, Mandeep R. Mehra, Carl J. Lavie, Youssef Rizk, Donald N. Forthal |
| 29 |
[GO] |
2020―Aug―16 |
Management of Thrombotic Complications in COVID-19: An Update |
Adrija Hajra, Sheetal Vasundara Mathai, Somedeb Ball, Dhrubajyoti Bandyopadhyay, Maedeh Veyseh, Sandipan Chakraborty, Carl J. Lavie, Wilbert S. Aronow |
| 30 |
[GO] |
2020―Jul―23 |
Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ? |
Vanessa Bianconi, Francesco Violi, Francesca Fallarino, Pasquale Pignatelli, Amirhossein Sahebkar, Matteo Pirro |
| 31 |
[GO] |
2020―Jul―21 |
Pharmaco-Immunomodulatory Therapy in COVID-19 |
John G. Rizk, Kamyar Kalantar-Zadeh, Mandeep R. Mehra, Carl J. Lavie, Youssef Rizk, Donald N. Forthal |
| 32 |
[GO] |
2020―May―25 |
The G-Quadruplex/Helicase World as a Potential Antiviral Approach Against COVID-19 |
Nadia Panera, Alberto Eugenio Tozzi, Anna Alisi |
